IFx-Hu3.0: Personalized Cancer Vaccine Delivered Intravenously

Preclinical Program in Development for the Treatment of B-Cell Malignancies, including Diffuse Large B-Cell Lymphoma (DLBCL)

IFx-Hu3.0 is leveraging the clinical validation of our leading IFx-Hu2.0 program and is being developed as an intravenous solution for the delivery of our proprietary emm55 mRNA targeting CD22, which is overexpressed on cancerous B-cells.

Emm55 mRNA codes for the same highly immunogenic bacterial protein utilized in our IFx-Hu2.0 program.  We are able to have tumor cells produce the emm55 bacterial protein by using a proprietary codon-optimized mRNA necessary to improve the efficiency of translation. Delivery of the mRNA causes this bacterial protein to be expressed on the surface of the tumor cells, priming the immune system to target and attack tumor cells by making them look like bacteria.

While we are initially targeting B-cell malignancies with IFx-Hu3.0, we expect intravenous delivery of our proprietary emm55 mRNA will result in the activation of a more robust immune response in malignancies with a high tumor burden.  

We are developing several methods by which to systemically deliver IFx-Hu3.0 via intravenous injection, including single-chain variable fragment (scFv) lipid nanoparticles and an exosomal mRNA delivery technology.

Program Highlights

  • Proprietary emm55 mRNA codon optimized for translational efficiency in mammalian (tumor) cells
  • Proprietary construct scFv-LPN (emm55 mRNA) targeting CD22 for B-cell malignancies
  • CD22 is validated target demonstrated by Genetec’s POLIVY® and Pfizer’s BESPONSA®
  • Opportunity to target multiple tumor-associated receptors
  • Next generation lipid nanoparticle (LPN) carriers

    • More efficient packaging that allows for systemic administration of mRNA
    • Better biodistribution